151 related articles for article (PubMed ID: 37131154)
21. Disparities in positive results and dissemination of randomized controlled trials in immuno-oncology.
Xu C; Zhang S; Zhu GL; Yang KB; Zhang Y; Mao YP; Tang LL; Liu Q; Huang Y; Ma J
Int Rev Immunol; 2023; 42(2):91-100. PubMed ID: 35712868
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
23. REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers.
Merrick S; Nankivell M; Quartagno M; Clarke CS; Joharatnam-Hogan N; Waddell T; O'Carrigan B; Seckl M; Ghorani E; Banks E; Edmonds K; Bray G; Woodward R; Bennett R; Badrock J; Hudson W; Langley RE; Vasudev N; Pickering L; Gilbert DC
Contemp Clin Trials; 2023 Jan; 124():107030. PubMed ID: 36519749
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
25. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
[TBL] [Abstract][Full Text] [Related]
26. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
27. A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for
He J; Liu Y; Liu C; Hu H; Sun L; Xu D; Li J; Wang J; Chen X; Lin R; Jiang Y; Zhang Y; Zhang W; Cheng Y; Wu X; Fang M; Li E; Xu Y; Chen Y; Li J; Cui Y; Pan Z; Zhang S; Yuan Y; Ding K
Technol Cancer Res Treat; 2023; 22():15330338231152350. PubMed ID: 36727222
[No Abstract] [Full Text] [Related]
28. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience.
Carr MJ; Sun J; DePalo D; Rothermel LD; Song Y; Straker RJ; Baecher K; Louie RJ; Stahlie EHA; Wright GP; Naqvi SMH; Kim Y; Sarnaik AA; Karakousis GC; Lowe MC; Delman KA; van Akkooi ACJ; Ollila DW; Collichio F; Zager JS
Ann Surg Oncol; 2022 Feb; 29(2):791-801. PubMed ID: 34648098
[TBL] [Abstract][Full Text] [Related]
29. Synthetic sling or artificial urinary sphincter for men with urodynamic stress incontinence after prostate surgery: the MASTER non-inferiority RCT.
Constable L; Abrams P; Cooper D; Kilonzo M; Cotterill N; Harding C; Drake MJ; Pardoe MN; McDonald A; Smith R; Norrie J; McCormack K; Ramsay C; Uren A; Mundy T; Glazener C; MacLennan G
Health Technol Assess; 2022 Aug; 26(36):1-152. PubMed ID: 35972773
[TBL] [Abstract][Full Text] [Related]
30. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
Manfredi S; Turpin A; Malka D; Barbier E; Laurent-Puig P; Zaanan A; Dahan L; Lièvre A; Phelip JM; Michel P; Hautefeuille V; Legoux JL; Lepage C; Tougeron D; Aparicio T
Dig Liver Dis; 2020 Oct; 52(10):1143-1147. PubMed ID: 32747302
[TBL] [Abstract][Full Text] [Related]
31. High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
Lertbutsayanukul C; Kitpanit S; Kannarunimit D; Chakkabat C; Oonsiri S; Thephamongkhol K; Puataweepong P; Katanyoo K; Sukhaboon J; Tovanabut C; Chongsathientham S; Treeratsapanich P; Soonthornrak J; Prayongrat A
Trials; 2022 Oct; 23(1):897. PubMed ID: 36273186
[TBL] [Abstract][Full Text] [Related]
32. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
Mulder EEAP; de Joode K; Litière S; Ten Tije AJ; Suijkerbuijk KPM; Boers-Sonderen MJ; Hospers GAP; de Groot JWB; van den Eertwegh AJM; Aarts MJB; Piersma D; van Rijn RS; Kapiteijn E; Vreugdenhil G; van den Berkmortel FWPJ; Hoop EO; Franken MG; Ryll B; Rutkowski P; Sleijfer S; Haanen JBAG; van der Veldt AAM
BMC Cancer; 2021 Mar; 21(1):323. PubMed ID: 33765967
[TBL] [Abstract][Full Text] [Related]
33. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
34. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
35. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.
Tong TML; van der Kooij MK; Speetjens FM; van Erkel AR; van der Meer RW; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Burgmans MC; Kapiteijn E
Trials; 2022 Feb; 23(1):137. PubMed ID: 35152908
[TBL] [Abstract][Full Text] [Related]
36. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
37. Early oral stepdown antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia (the INVEST trial): study protocol for a multicentre, randomised controlled, open-label, phase III, non-inferiority trial.
Lee IR; Tong SYC; Davis JS; Paterson DL; Syed-Omar SF; Peck KR; Chung DR; Cooke GS; Libau EA; Rahman SBA; Gandhi MP; Shi L; Zheng S; Chaung J; Tan SY; Kalimuddin S; Archuleta S; Lye DC
Trials; 2022 Jul; 23(1):572. PubMed ID: 35854360
[TBL] [Abstract][Full Text] [Related]
38. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
39. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.
Bhave P; Hong A; Lo SN; Johnson R; Mangana J; Johnson DB; Dulgar O; Eroglu Z; Yeoh HL; Haydon A; Lodde GC; Livingstone E; Khattak A; Kähler K; Hausschild A; McArthur GA; Menzies AM; Long G; Wang W; Carlino MS
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36889810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
